NCT07105111 - A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

SchizophreniaSchizoaffective DisorderBipolar DisorderMajor Depressive DisorderTardive Dyskinesia

Interventions

DRUG

Valbenazine

Valbenazine capsules for oral administration.

Trial Locations (8)

RECRUITING

Neurocrine Clinical Site, Marietta

RECRUITING

Neurocrine Clinical Site, Hialeah

RECRUITING

Neurocrine Clinical Site, Miami

RECRUITING

Neurocrine Clinical Site, Tampa

RECRUITING

Neurocrine Clinical Site, Bonita Springs

RECRUITING

Neurocrine Clinical Site, Bryant

RECRUITING

Neurocrine Clinical Site, Fountain Valley

RECRUITING

Neurocrine Clinical Site, Orange